Molecular characterisation of acquired and overproduced chromosomal blaAmpC in Escherichia coli clinical isolates

Alonso, Noemí Acedo; Miró, Elisenda; Pascual, Vanesa; Rivera, Alba; Simó, María; Garcia, Maria Consol; Xercavins, Mariona; Morera, M.; Espejo, Elena; Gurguí, Mercé; Pérez, J. Enrique; Rodríguez-Carballeira, Mónica; Garau, Javier; Calbo, Esther; Navarro, Ferrán; Mirelis, Beatriz; Coll, Pere

doi:10.1016/j.ijantimicag.2015.10.007

Cited by 27 publications

(26 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There were two strains (SW-007 and TR-032) that were found to have insertions (thymine) at position -20. Although a similar mutation has been reported elsewhere (Jorgensen et al 2010;Alonso et al 2016), this may be the first report of this mutation in isolates from the UK.…”

supporting

confidence: 83%

“…Other studies have found a higher prevalence for this particular mutation (Mulvey et al 2005;Jorgensen et al 2010;Mammeri et al 2010;Alonso et al 2016), with one reporting a prevalence of 100% (Bogaerts et al 2010). There were two strains (SW-007 and TR-032) that were found to have insertions (thymine) at position -20.…”

mentioning

confidence: 84%

“…Unusually, the -32 mutation (T to A) was the most common (63%); whereas other studies have reported a higher prevalence for the -42 mutation (Mulvey et al 2005;Mammeri et al 2008;Bogaerts et al 2010;Jorgensen et al 2010;Alonso et al 2016). We therefore set out to investigate whether this was also the case in other parts of the South West of England.…”

mentioning

confidence: 95%

See 2 more Smart Citations

Multi-locus sequence typing of Escherichia coli isolates with acquired ampC genes and ampC promoter mutations

Lewis

Moore

Arnold

et al. 2016

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

Disclaimer UWE has obtained warranties from all depositors as to their title in the material deposited and as to their right to deposit such material. UWE makes no representation or warranties of commercial utility, title, or fitness for a particular purpose or any other warranty, express or implied in respect of any material deposited.UWE makes no representation that the use of the materials will not infringe any patent, copyright, trademark or other property or proprietary rights. UWE accepts no liability for any infringement of intellectual property rights in any material deposited but will remove such material from public view pending investigation in the event of an allegation of any such infringement. PLEASE SCROLL DOWN FOR TEXT. Multi-Locus Sequence Typing of Escherichia coli AbstractMulti-locus sequence typing was used to reveal a high degree of diversity amongst the E. coli isolates with AmpC plasmid genes, and a high prevalence of the -32 mutation present.Cephalosporins are broad-spectrum antibiotics used to treat a wide range of clinical infections. Some serious infections, such as sepsis, can be harder to treat and result in higher mortality rates if strains are cephalosporin-resistant (de Kraker et al. 2011). The most common cause of cephalosporin resistance in Escherichia coli is production of the CTX-M beta-lactamase enzyme (Potz et al. 2006).AmpC beta-lactamase hyper-production, however, is another cause in E. coli, with the enzyme

show abstract

supporting

confidence: 83%

mentioning

confidence: 84%

See 1 more Smart Citation

Multi-locus sequence typing of Escherichia coli isolates with acquired ampC genes and ampC promoter mutations

Lewis

Moore

Arnold

et al. 2016

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

show abstract

“…Presumptive qAmpC producers were preliminarily identified using phenotypic criteria and bla qAmpC genes were further identified by PCR and sequencing [8] . Isolates carrying bla qAmpC were also analysed for the presence of ESBL, carbapenemases or plasmid-mediated quinolone resistance genes [PMQR; qnr and aac(6’)-Ib-cr ] [2, 8, 11] . K. variicola , E. coli phylogroups, and E. coli O25b-ST131 were identified as described [10, 12] .…”

Section: Methodsmentioning

confidence: 99%

“…The worldwide contemporary epidemiology of Enterobacteriaceae resistant to broad-spectrum cephalosporins seems to be largely dominated by extended-spectrum β-lactamases (ESBL) than acquired AmpC β-lactamases (qAmpC) [1] . However, the occurrence and clinical impact of Enterobacteriaceae producing qAmpC is probably underestimated, since qAmpC producers are difficult to identify by conventional methods and qAmpC expression is frequently masked by other resistance mechanisms [2, 3] . Recent studies described an increase of specific qAmpC enzymes among clinical Enterobacteriaceae [1, 2, 4] , mostly CMY-2-producing Escherichia coli associated either with hospital or community infections and DHA-1-producing Klebsiella pneumoniae especially linked to nosocomial outbreaks [2, 3, 5, 6] .…”

Section: Introductionmentioning

confidence: 99%

Significant temporal shifts on clonal and plasmid backgrounds of Enterobacteriaceae producing acquired AmpC in Portuguese clinical settings

Novais

Rodrigues

et al. 2019

Preprint

View full text Add to dashboard Cite

Running title: Molecular epidemiology of qAmpC among clinical Enterobacteriaceae. 30 31 # These authors were equally contributed in this work. 32 33 34 Abbreviations 35 CS, conserved segment; ESBL, extended-spectrum β-lactamases; ICE, integrative and 36 conjugative element; icr-AmpC, inducible chromosomal AmpC; KL, capsular locus; MDR, 37 multidrug-resistant; MRR, multidrug resistance region; PMQR, plasmid-mediated quinolone 38 resistance; qAmpC, acquired AmpC β-lactamases; VR1, variable region 1. 39 ABSTRACT 40 OBJECTIVES: To provide detailed molecular data on clinical acquired AmpC (qAmpC)-41producing Enterobacteriaceae from two different periods (42 order to clarify the contribution of clonal and plasmid genetic platforms for the current 43 epidemiological scenario concerning extended-spectrum beta-lactams resistance. 44 METHODS:We analysed 1246 Enterobacteriaceae non-susceptible to third-generation 45 cephalosporins from 2 hospitals and 1 community laboratory between 2010 and 2013. 46Bacterial identification, antibiotic susceptibility, identification of qAmpC and plasmid-47 mediated quinolone resistance genes, clonal (PFGE, MLST) and plasmid (S1-/I-CeuI-PFGE, 48 replicon typing, hybridization) analysis were performed by standard methods. WGS was 49 performed in two ST11-K. pneumoniae isolates harbouring DHA-1. 50 RESULTS:The occurrence of qAmpC was lower (2.6%) than that observed in a previous 51 survey (7.4%), and varied slightly over time. Isolates produced DHA-1 (53%), CMY-2 (44%) 52 or DHA-6 (3%), but significant epidemiological changes were observed in the two surveys. 53While DHA-1 persisted in different institutions by selection of a worldwide epidemic IncR 54 plasmid in a ST11 harbouring KL105, CMY-2 rates increased over time linked to IncI1 55 plasmids (instead of IncK or IncA/C 2 ) in multiple E. coli clones. 56 CONCLUSIONS:The higher frequency of DHA-1 qAmpC in these species contrasts with 57 the scenario of most European countries. Furthermore, the different genetic backgrounds 58 associated with either ESBL or qAmpC in our country might have contributed to their 59 differential expansion. 60 61 IncR. 63 64 65 The worldwide contemporary epidemiology of Enterobacteriaceae resistant to broad-66 spectrum cephalosporins seems to be largely dominated by extended-spectrum β-lactamases 67 (ESBL) than acquired AmpC β-lactamases (qAmpC) [1]. However, the occurrence and 68 clinical impact of Enterobacteriaceae producing qAmpC is probably underestimated, since 69 qAmpC producers are difficult to identify by conventional methods and qAmpC expression is 70 frequently masked by other resistance mechanisms [2, 3]. Recent studies described an 71 increase of specific qAmpC enzymes among clinical Enterobacteriaceae [1, 2, 4], mostly 72 CMY-2-producing Escherichia coli associated either with hospital or community infections 73 and DHA-1-producing Klebsiella pneumoniae especially linked to nosocomial outbreaks [2, 74 3, 5, 6]. 75 76 In Portugal, relevant epidemiological changes regarding resistance to extended-spectr...

show abstract

Emergence of co-production of plasmid-mediated AmpC beta-lactamase and ESBL in cefoxitin-resistant uropathogenic Escherichia coli

Ghosh

Mukherjee

2016

Eur J Clin Microbiol Infect Dis

View full text Add to dashboard Cite

Plasmid-mediated AmpC (pAmpC) and ESBL co-production was detected in Escherichia coli a major etiologic agent of urinary tract infection. Isolates resistant to cefoxitin by CLSI methodology were tested for pAmpC beta-lactamase using phenylboronic acid and ESBLs by combined disk diffusion method. pAmpC/ESBL genes were characterized by PCR and sequencing. Transconjugation experiments were done to study the transfer of pAmpC and ESBL production from clinical isolates as donor to E. coli J53 AziR as recipient. Incompatibility groups of transmissible plasmids were classified by PCR-based replicon typing (PBRT). Among 148 urine culture positive isolates, E. coli was reported in 39.86 % (59/148), with 93.22 % (55/59) of cefoxitin resistance. pAmpC production was detected in 25, with varied distribution of blaCMY-2 and blaDHA-1type genes alone (n = 13 and 7 respectively) or in combination (n = 5). ESBL co-production was observed in 88 % (22/25) of pAmpC producing isolates with predominance of blaTEM (n = 20). Twenty-three transconjugants showed transmission of pAmpC-and ESBL-resistant genes with co-carriage of blaCMY-2 and blaTEM (n = 15) in plasmids of IncF type (n = 9) being predominant, followed by IncI1 (n = 4) and IncH1 (n = 2) in combination. All clinical isolates were clonally diverse. Resistance against different beta-lactams in uropathogenic E. coli has been an emerging concern in resource- poor countries such as India. Knowledge on the occurrence of AmpC beta-lactamases and ESBL amongst this pathogen and its transmission dynamics may aid in hospital infection control.

show abstract

Molecular characterisation of acquired and overproduced chromosomal blaAmpC in Escherichia coli clinical isolates

Cited by 27 publications

References 36 publications

Multi-locus sequence typing of Escherichia coli isolates with acquired ampC genes and ampC promoter mutations

Multi-locus sequence typing of Escherichia coli isolates with acquired ampC genes and ampC promoter mutations

Significant temporal shifts on clonal and plasmid backgrounds of Enterobacteriaceae producing acquired AmpC in Portuguese clinical settings

Emergence of co-production of plasmid-mediated AmpC beta-lactamase and ESBL in cefoxitin-resistant uropathogenic Escherichia coli

Contact Info

Product

Resources

About